DE2840498C2 - Pharmaceutical preparations for the treatment of psoriasis - Google Patents
Pharmaceutical preparations for the treatment of psoriasisInfo
- Publication number
- DE2840498C2 DE2840498C2 DE19782840498 DE2840498A DE2840498C2 DE 2840498 C2 DE2840498 C2 DE 2840498C2 DE 19782840498 DE19782840498 DE 19782840498 DE 2840498 A DE2840498 A DE 2840498A DE 2840498 C2 DE2840498 C2 DE 2840498C2
- Authority
- DE
- Germany
- Prior art keywords
- parts
- acid
- psoriasis
- treatment
- pharmaceutical preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Die Erfindung betrifft den im Anspruch gcnuu gekennzeichneten Gegenstand.The invention relates to the subject matter characterized in claim gcnuu.
Gemäß »Federation Proceedings« !5 (!956) S. 971 —976 (D. Shemin) entsteht durch Kondensation von Glyzin mit Succinat ό-Aminolaevulinsäure, daraus durch oxydierende Desaminierung j'-Kelogliilarsäurehalbaldchyd b/w. vKelojilutarsäure. bekanntlich wird diese Säure leicht zu Glutaminsäure transaminicrt, die nun ihrerseits z. B. Oxalessigsäure zu Asparaginsäure transaminieren kann. Es soll damit deutlich gemacht werden, daß man auch ohne den sogenannten Zitronensäurecyclu.% zur Ketoglutarsäure gelangt. Überdies war Zitronensäure bei der Behandlung von Psoriasis gänzlich wirkungslos. Die Bereitstellung von Glyzin ermöglicht darüber hinaus die Bildung von Serin. In den Schuppen der Psoriatikcr fehlen eine Reihe von Aminosäuren oder gewisse Mengen davon, wie z. B. Glyzin und Asparaginsäure (in der gesunden Haut zu ca. 30% und 6% enthalten). Serin, L-Cysicin, L-Mcthionin und verschiedene andere weisen in den Schuppen ebenfalls ein signifikantes Defizit auf. Ls war aber nicht naheliegend, daß gerade diese beiden Aminosäuren zusammen mil Askorbinsäure in genau bezeichneten Mengenverhältnis eine besondes vorteilhafte Wirkung ausüben. Die Behandlung der sogenannten Psoriasisnägel bereitete nämlich noch immer erhebliche Schwierigkeiten. Einbc/ogen in die Therapie wurde auch Vitamin C. Sie steuert den Abbau der aromatischen Aminosäurcsäuren und greift in biologische Oxydationsvorgänge ein, die let/tcn lindes komplexgcsteucrtc Reaktionen sind.According to "Federation Proceedings"! 5 (! 956) p. 971-976 (D. Shemin) is formed by condensation of glycine with succinate ό-aminolaevulinic acid, from it by oxidizing deamination of j'-Kelogliilar acid half aldehyde b / w. vKelojilutaric acid. known to be this Acid easily transaminicrt to glutamic acid, which is now on their part z. B. oxaloacetic acid can transaminate to aspartic acid. It should be made clear that even without the so-called citric acid cycle.% reaches ketoglutaric acid. In addition, citric acid has been used in the treatment of psoriasis completely ineffective. The provision of glycine also enables the formation of serine. In the Dandruff in psoriasis is missing a number of amino acids or certain amounts thereof, such as B. Glycine and aspartic acid (about 30% and 6% in healthy skin). Serine, L-cysicine, L-methionine and several others are also significantly deficient in the scales. But it wasn't It is obvious that precisely these two amino acids together denoted ascorbic acid in Quantity ratio exert a particularly advantageous effect. Treatment of the so-called psoriasis nails namely still caused considerable difficulties. Vitamin was also included in the therapy C. It controls the breakdown of aromatic amino acid acids and intervenes in biological oxidation processes one, the let / tcn lindes complex-controlled reactions are.
Aus der DF.-OS 25 JO 372 ist es /war bekannt. Fumarsäure, deren Mono- oder Diester zusammen mit Säuren, Alkalisal/cn von Askorbinsäure ii. anderen Säuren gegen Psoriasis, ggf. noch mil VitaminA-Säure zu verabreichen, und aus der DF.-OS 27 03 964 ist /war auch zu entnehmen, daß eine Mischung von Fuinarsäu rcn oder deren Estern und Salzen zusammen mit Glycin und ggf. sekundären Phosphaten zur Behandlung von Psoriasis geeignet ist. Demgegenüber war es aber völlig überraschend, daß die zusätzliche Gabe von I. Methionin und L-Cystein und freier Askorbinsäure in bestimmten Gewichtsvcrhälinissen eine weitere Verbesserung der l'soriasisthcnipie bewirkt. Der /iisat/ dieser drei Verbindungen zu dem bekannten Mitteln beeinflußt nämlich in völlig unerwarteter Weise die bei Psoriasis pathologisch destrukturierten Nägel und auch Kopfhaut in günstiger Weise und führt sie bei entsprechend langer, kontinuierlicher Einnahme von mehreren Monaten in den Normalzustand zurück. Dies konnte bei lange Zeit erfolglos behandelten Psoriatikern in fünf Fällen ohne einzigen Mißerfolg beobachtet werden.It is / was known from DF.-OS 25 JO 372. Fumaric acid, their mono- or diesters together with Acids, alkaline salts / cn of ascorbic acid ii. others Acids against psoriasis, possibly with vitamin A acid to be administered, and from DF.-OS 27 03 964 is / was also to be found that a mixture of Fuinarsäu rcn or their esters and salts together with glycine and possibly secondary phosphates for the treatment of Psoriasis is suitable. In contrast, it was completely surprising that the additional administration of I. Methionine and L-cysteine and free ascorbic acid in certain weight ratios provide a further improvement the l'soriasisthcnipie causes. The / iisat / of these three connections to the known agent influences namely in a completely unexpected manner the Psoriasis pathologically destructured nails and also scalp in a beneficial way and leads to them correspondingly long, continuous intake of several months back to normal. this was observed in five cases without a single failure in psoriatic patients who had been treated unsuccessfully for a long time will.
Herstcllungsbeispiele für die interne Applikation Plv.-Mischung(I)Production examples for internal application Plv.-mixture (I)
24 Teile Fumarsäuredimethylester24 parts of dimethyl fumarate
8 Teile Fumarsäure8 parts of fumaric acid
24 Teile Magnesiumfumarat24 parts of magnesium fumarate
12 Teile Calciumfumarai12 parts calcium fumarai
12 Teile Eisenfumarat12 parts of ferrous fumarate
1,6 Teile Manganfumarut1.6 parts of manganese fumarut
2Ü 0,4 Teile Kupferfumarai 2Ü 0.4 parts copper fumarai
4.0 Teile Dilithiumfumarat4.0 parts dilithium fumarate
12,0Teile CaSO4 - 2 H,O(Gips)12.0 parts CaSO 4 - 2 H, O (plaster)
2,0 Teile Zinkoxyd oder Zinkfumarat 2.0 parts of zinc oxide or zinc fumarate
100 Teile (Mil)100 parts (mil)
Darauf werdenBe on it
50Teile der Mischung(l)mil50 parts of the mixture (l) mil
30 Teilen Glyzin30 parts of glycine
8 Teilen Ascorbinsäure
jo 8 Teilen L-Cystein8 parts of ascorbic acid
jo 8 parts of L-cysteine
4 Teilen L-Mcthionin vermischt.4 parts of L-methionine mixed.
Applikation in Gelalinckapscln 0,5 — I g.Application in gelatin capsules 0.5 - 1 g.
Plv.-Mischung(2)Plv. Mixture (2)
30 Teile Fumarsäuredimethylesicr30 parts of fumaric acid dimethyl sicr
9 Teile Fumarsäure9 parts of fumaric acid
10 Teile Calciumsalzdcs Fumarsäurc-10 parts calcium salt of fumaric acid
monoacthyleslersmonoacthyleslers
10 Teile Magncsiumsal/ des Fumarsäuremonoaclhyleslers 10 parts of Magncsium / Fumaric acid monoaclylethyl
lOTcile Zinksalzdcs Fumarsa'urc-lOTcile zinc saltdcs Fumarsa'urc-
nionoacthylcsicrs
10 Teile Eisensalz des FumarsaiiremonoacihylcMers
5 Teile Mangansalz des l'unuirsäure-nionoacthylcsicrs
10 parts of the iron salt of fumaric acid monoacihylcMers
5 parts manganese salt of the l'unuir acid
monoacihylcsiers
I Teil Kupfersal/. des Fumarsäiirc-monoacihylcsiers
I part of copper sal /. of the Fumarsäiirc-
monoaethyleslers
10 Teile Dililhiumfumarat
5Teile CaSO4 · 2 H.O
lOOTcilrmonoaethyleslers
10 parts of dililium fumarate
5 parts CaSO 4 · 2 HO
lOOTcilr
Darauf vermischt manThen one mixes up
- 55 50 Teile der Mischung (2) mil 30 Teilen Gly/.in
8 Teilen Ascorbinsäure
8 Teilen I .-Cystein und
4 Teilen L-Melhionin55 50 parts of the mixture (2) with 30 parts Gly / .in
8 parts of ascorbic acid
8 parts I. -cysteine and
4 parts of L-melhionin
f>o Applikation in Gelatinckapscln 0.3-0.8 gf> o Application in gelatin capsules 0.3-0.8 g
mit Flüssigkeit,
1 χ am Tagdircki vor Frühstück /.. H.with liquid,
1 χ on Tagdircki before breakfast / .. H.
Claims (1)
enthalten sind.c) 4 parts by weight L-methionine
are included.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19782840498 DE2840498C2 (en) | 1978-09-18 | 1978-09-18 | Pharmaceutical preparations for the treatment of psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19782840498 DE2840498C2 (en) | 1978-09-18 | 1978-09-18 | Pharmaceutical preparations for the treatment of psoriasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2840498B1 DE2840498B1 (en) | 1979-08-02 |
| DE2840498C2 true DE2840498C2 (en) | 1980-04-10 |
Family
ID=6049713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19782840498 Expired DE2840498C2 (en) | 1978-09-18 | 1978-09-18 | Pharmaceutical preparations for the treatment of psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE2840498C2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5359128A (en) * | 1991-01-18 | 1994-10-25 | Izhak Blank | Malic acid derivatives and compositions for the treatment of psoriasis |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL97012A0 (en) * | 1990-01-30 | 1992-03-29 | Gist Brocades Nv | Topical preparations for treating human nails |
| DE19831798A1 (en) * | 1998-07-15 | 2000-01-27 | Mandorlo Investment Gmbh Luxem | Microcirculation improving skin and tissue care or treatment composition, containing salts, aminoacids and peroxide, used as cosmetic, medicament or nutrient supplement |
| DE19853487A1 (en) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Use of dialkyl fumarate for treating transplant rejection and autoimmune disease |
| DE10133202A1 (en) * | 2001-07-07 | 2003-01-16 | Beiersdorf Ag | Topical compositions containing osmolytes, useful e.g. for treating or preventing dry skin or inflammatory conditions of the skin, e.g. eczema, polymorphic light dermatosis or psoriasis |
| AU2004269903B2 (en) | 2003-09-09 | 2010-09-02 | Biogen International Gmbh | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| US20140099364A2 (en) | 2004-10-08 | 2014-04-10 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| ES2916649T3 (en) | 2007-02-08 | 2022-09-21 | Biogen Ma Inc | Compositions and uses for the treatment of multiple sclerosis |
| PT2379063E (en) | 2009-01-09 | 2013-05-03 | Forward Pharma As | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
-
1978
- 1978-09-18 DE DE19782840498 patent/DE2840498C2/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5359128A (en) * | 1991-01-18 | 1994-10-25 | Izhak Blank | Malic acid derivatives and compositions for the treatment of psoriasis |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2840498B1 (en) | 1979-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69017654T2 (en) | ANALGETIC LOTION TO BE APPLIED ON THE OUTSIDE AND METHOD FOR THE PRODUCTION THEREOF. | |
| DE2840498C2 (en) | Pharmaceutical preparations for the treatment of psoriasis | |
| EP0037488B1 (en) | Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes | |
| DE3875867T2 (en) | CALCIUM ADDITIVES. | |
| CH695983A5 (en) | Tetraiodthyropropionsäure or Tetraiodthyroessigsäure for producing a dermatological preparation. | |
| DE3880587T2 (en) | USE OF CERTAIN CALCIUM-CITRATE MALATES FOR THE PRODUCTION OF A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF OSTEOPOROSIS. | |
| DE2616491C2 (en) | Medicines that inhibit platelet agglutination | |
| DE2455203C2 (en) | ||
| DE60216292T2 (en) | CALCIUM TRIFLUORACETATE WITH CYTOTOXIC EFFECT | |
| DE3543801C2 (en) | ||
| EP0207193A2 (en) | Synergetic combination of flupirtin and 4-acetamido-phenol | |
| DE2326301A1 (en) | NEW PHARMACEUTICAL PREPARATIONS BASED ON DERIVATIVES WITH EBURNAN SKELETON AND / OR THEIR SALT | |
| DE69533742T2 (en) | Use of proline and / or derivatives as anti-hepatitis agents | |
| DE3809625C2 (en) | ||
| DE1667903C3 (en) | Use of cysteine derivatives for the production of orally administrable agents for combating seborrhea | |
| DE1692463C3 (en) | Livestock and poultry growth and development promoting agent containing cysteine and homocysteine | |
| DE10119946A1 (en) | Addition of conjugated linoleic acid, creatine and/or L-carnitine to an effervescent tablet, useful for e.g. increasing muscle protein synthesis, increasing fat burnoff and increasing performance | |
| DE2221281C3 (en) | Pharmaceutical preparations with anti-inflammatory and analgesic effects | |
| DE2753140C2 (en) | Medicines used to treat stomach ulcers | |
| DE2635293A1 (en) | SALT MIXTURE, IN PARTICULAR EASILY ASSIMILABLE MEDICINAL MIXTURE WITH INCREASED SOLUBILITY, CONTAINS CALCIUM SALTS AND / OR MAGNESIUM SALTS | |
| DE69109815T2 (en) | Anhydrous composition containing lactulose. | |
| EP0217041A1 (en) | Dentifrice | |
| DE69009538T2 (en) | Therapeutic composition with anti-aggregation effects on platelets. | |
| DE2245826C3 (en) | Salts of N-cyano-ethyl-N'-m-chlorophenyl-piperazine | |
| DD154802A5 (en) | PROCESS FOR PREPARING AN INJECTABLE PHARMACEUTICAL PREPARATION OF PROLONGED EFFECT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8339 | Ceased/non-payment of the annual fee |